In our study, the TGF-β/Smad pathway was activated in response to oxalate crystal-induced renal injury and was reversed by FFJQC therapy, indicating that the protective effect of FFJQC on crystal-induced kidney injury may be achieved by inhibiting the TGF-β/Smad pathway. Here, TGFB1 is linked to kidney injury.